Sirturo (bedaquiline) – a diarylquinalone – acts against Mycobacterium and it is approved by FDA by December 2012. Report claims that the approval is based on phase 2 clinical trial with 394 patients. Its acts by inhibiting the Mycobacterial F1F0-adenosine triphosphate (ATP) synthase – this MoA is novel among other anti tuberculosis drug.
Sirturo is expected to generate revenue between $400 and $500 million and it was developed by (tibotec) Johnson & Johnson (J&J) and the TB Alliance.
For more information please visit the report by Randy Osborne .